<DOC>
	<DOCNO>NCT00878761</DOCNO>
	<brief_summary>This Phase 2 study multi-center , randomize , double-blind , placebo-controlled , single follow multiple dose , dose escalation study design evaluate safety , tolerability , pharmacokinetics , immunogenicity , impact STX-100 gene protein expression αvβ6 relate TGF-β-inducible gene ( include tubulointerstitial injury , epithelial function , IF/TA relate gene ) renal transplant patient biopsy .</brief_summary>
	<brief_title>Study STX-100 Renal Transplant Patients With Interstitial Fibrosis Tubular Atrophy ( IF/TA )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<criteria>Consenting adult patient , 18 ( legal age consent ) 65 year old , male female . eGFR ≥ 25 ml/min ( CockcroftGault formula ) . Six 60 month post renal transplant initiation screening . Qualifying renal biopsy obtain within 8 week prior randomization histologic evidence ≥ Grade 2 IF/TA ( Banff score ) without morphologic evidence treatable etiology ( e.g. , BK virus nephropathy , chronic obstruction ) . Adequate bone marrow liver function Weight 40110 kg . Female patient must surgically sterile , postmenopausal ( minimum 1 year without menses verify follicularstimulating hormone [ FSH ] level ) , agree use contraception time sign informed consent form 16 week follow last injection study medication . Male patient must also agree use birth control either partner , appropriate , time signing informed consent form 16 week follow last injection study medication . Recipient multiorgan transplant . History Tcell mediate rejection ( TCMR ) within 3 month prior randomization . Patients receive high dose corticosteroid time screen . Histologic evidence acute TCMR ( ≥ Banff Grade 1A ) qualify renal biopsy study . Patients 'borderline ' change ( Banff criterion ) qualify renal biopsy eligible study Principal Investigator believe treatment TCMR warrant . Prior current histologic evidence polyomavirus BK virus nephropathy . Any histologic finding qualify renal biopsy Investigator believe warrant modify patient 's current therapy . Evidence active tissue invasive cytomegalovirus EpsteinBarr virus infection . History malignancy , include carcinoma posttransplant lymphoproliferative disorder . History chronic pulmonary disease smoker within past 5 year 15 packyears exposure . Serious local infection systemic infection within 3 month prior screen . Surgery within 3 month prior Day 1 ( minor cosmetic surgery , minor dental procedure , percutaneous kidney transplant biopsy ) . Positive test HBsAg , HCV , HIV antibody screen . Treatment another investigational drug , investigational device , approve therapy investigational use within 1 month prior dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Renal transplant</keyword>
	<keyword>Interstitial fibrosis tubular atrophy</keyword>
	<keyword>Chronic allograft dysfunction</keyword>
	<keyword>Chronic allograft nephropathy</keyword>
	<keyword>kidney transplant</keyword>
</DOC>